Seeking Alpha
18 Nov 2026, 14:49 UTC · 4h ago
Pfizer: The Patent Cliff Fears Are Overblown
Impact · against what's priced in
Pfizer's moderate guidance raise and strong Eliquis performance provide a slight positive catalyst by mitigating immediate patent cliff concerns. However, the magnitude of the EPS revision is small, limiting the overall impact on the stock price.
- PFE+0.20
No priced-in read yet
- In context
The increase in 2026 adjusted diluted EPS guidance to $2.95-$3.05 and a 25.2% year-over-year revenue growth for Eliquis suggest that current growth in key franchises is offsetting the expected three-year patent expiration cycle.
Read from the article alone

Top 1 mover · tap to explore




